Browse the evidence

The exercise goal of 10,000 steps/day was unachievable for the participants.

Practitioners should consider setting realistic exercise goals for pregnant women to enhance adherence.

There are no statistically significant differences in peak EMG amplitude between high-load and low-load resistance exercises.

Practitioners can expect similar peak muscle activation levels regardless of load intensity during bench press.

GIPR agonism may reduce gastrointestinal adverse effects associated with GLP-1R agonism.

GIPR agonists may help mitigate gastrointestinal side effects for patients using GLP-1R agonists.

Concurrent exposure to liraglutide and a GIPRA is hypothesized to produce fewer GI adverse effects than exposure to liraglutide alone.

This suggests a potential strategy for reducing side effects in patients using liraglutide.

Set structure (cluster-set vs. traditional-set) seems to be of less importance for changes in bench press velocity and power.

Practitioners may choose either set structure without concern for significant differences in outcomes.

Several compounds targeting the central nervous system and/or periphery are in development for obesity treatment.

Practitioners should stay informed about new drug developments targeting obesity.

There were no differences for psychophysiological variables between traditional resistance training (RT) and high velocity resistance training (HVRT).

Practitioners can expect similar psychophysiological outcomes from either training modality in this demographic.

There has been a revolution in understanding the molecular and neural control of appetite and body weight.

Understanding these mechanisms can inform treatment strategies for obesity.

Weight loss had mixed associations with cognitive scores.

Weight loss may not uniformly benefit cognitive function, and effects can vary based on initial weight status.

Associations between improvements in glycemic control and cognitive performance may differ by adiposity and cardiovascular disease history.

Consider individual health profiles when assessing the impact of glycemic control on cognitive function.

GLP-1RA users had a lower risk of dementia (HR, 0.63; 95% CI, 0.50-0.81) compared to other antidiabetic drug users.

Practitioners may consider GLP-1RAs as a treatment option for reducing dementia risk in this population.

Pre-exhaustion does not alter the neuromuscular activity of the target muscle in multi-joint exercise.

Practitioners should note that pre-exhaustion does not change muscle activation patterns.

The SLOW group reported a higher rating of perceived exertion (RPE) than the FAST group.

Strength and conditioning professionals should consider RPE when designing training programs with different tempos.

Intranasal delivery of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) could overcome the limitations of subcutaneous administration for obesity treatment.

Practitioners should consider intranasal delivery methods for improving patient adherence and reducing side effects.

Low fat intake is associated with a higher risk of all-cause dementia (HR 1.42 (95%CI: 1.11-1.82)).

Practitioners should be cautious about recommending very low fat diets for older adults due to potential dementia risk.

Chronic co-administration of OXT and GLP-1 decreases body weight without changing food intake.

Combining OXT with GLP-1 may be an effective strategy for reducing body weight in obese populations.

Single injection of OXT/GLP-1 additively decreases food intake.

Using OXT in conjunction with GLP-1 may enhance appetite suppression effects.

Allodynia was observed in 4 patients associated with dose escalation of semaglutide.

Clinicians should be aware of the potential for allodynia in patients taking semaglutide.

BI 1820237 treatment was associated with transient nausea and vomiting at higher doses.

Practitioners should monitor for gastrointestinal side effects when prescribing BI 1820237.

Amylin promotes satiation and recruits multiple central nervous system pathways to regulate food intake.

Understanding amylin's role can help in developing obesity treatments.

Small-molecule GLP1RAs regulate both homeostatic and hedonic feeding through parallel neural circuits.

Practitioners can consider the dual impact of small-molecule GLP1RAs on different feeding behaviors.

GLP1RAs suppress the consumption of palatable foods by reducing dopamine release in the nucleus accumbens.

Understanding this mechanism can help in developing strategies to manage palatable food consumption.

Targeted deletion of the receptor in central amygdalar neurons diminishes the anorectic efficacy of GLP1RAs for reward-driven intake.

This finding highlights the importance of specific neural receptors in the effectiveness of weight loss drugs.

Intestinally derived messengers, including gut hormones and microbial metabolites, regulate feeding behavior.

Understanding these signals can help in developing targeted obesity treatments.